SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- October 09, 2006 -- Theravance, Inc. (NASDAQ: THRX) announced today that the first patient was dosed in a Phase 2 clinical study of TD-5108, an investigational compound for the treatment of chronic constipation and other disorders related to reduced gastrointestinal (GI) motility. The goal of this program is to develop a product with once-a-day oral dosing and improved efficacy relative to current therapy.
